**Type 1 and 2 diabetes mellitus: comprehensive fracture risk relationships in UK Biobank**

Elizabeth M Curtis,1,2 Rebecca J Moon1,3, Stefania D’Angelo1, Zahra Raisi-Estabragh4,5, Cyrus Cooper1,2,6, Nicholas C Harvey1,2

1.MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton UK

2.NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital NHS Foundation Trust, Southampton, UK

3. Department of Paediatric Endocrinology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

4. Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, UK

5. William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK

6. NIHR Oxford Biomedical Research Centre, University of Oxford, UK

**Corresponding author:**

Professor Nicholas Harvey, MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK

Email: nch@mrc.soton.ac.uk

**Abstract**

We aimed to investigate associations between diabetes mellitus and incident fracture, stratified by diabetes type (1 or 2), disease duration and microvascular complications of diabetes. This prospective cohort analysis used data from the UK Biobank, a large population-based cohort of participants recruited 2006-2010 at age 40-69 years. The exposure was type 1 or type 2 diabetes at baseline, with the outcome of first incident osteoporotic fracture. Poisson regression was used to calculate incidence rate ratios (IRRs) for osteoporotic fracture to investigate prospective relationships between diabetes type 1 or 2 and fracture risk independent of traditional clinical risk factors, estimated bone mineral density by heel ultrasound (eBMD), adiposity, and C-reactive protein. The role of diabetic microvascular complications and associations between diabetes duration and fracture risk were studied. There were 498,949 participants (271,882 women, mean age 56 years; 227,067 men, 57 years). In fully adjusted models, type 1 and 2 diabetes were associated with increased fracture risk [type 1; IRR: 2.93 (95%CI:2.37,3.62); type 2: 1.25 (1.14,1.38)], similar by sex. The magnitude of risk associated with type 2 diabetes increased with duration of disease. Increasing number of microvascular complications was associated with greater fracture risk [any vs no complications, IRR 2.03 (1.57,2.62)]. Diabetes is associated with increased risk of fracture (magnitude of effect greater in type 1 than type 2 diabetes). Associations were partly independent of traditional risk factors, adiposity, eBMD and CRP. Type 2 diabetes disease duration and the presence of microvascular complications in both types were dose-dependent risk factors for fracture.

**Keywords**

Osteoporosis; epidemiology; type 1 diabetes mellitus; type 2 diabetes mellitus; fracture

**Funding**

The work was supported by the UK Medical Research Council (MRC) [MC\_PC\_21003; MC\_PC\_21001], National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton, and University Hospital Southampton NHS Foundation Trust, NIHR Oxford Biomedical Research Centre, University of Oxford, Wellcome Trust (209233/Z/17/Z). EMC has been supported by the Wellcome Trust (201268/Z/16/Z), by an NIHR Academic Clinical Lectureship and a grant from the American Society for Bone and Mineral Research. RJM is funded by an NIHR Academic Clinical Lectureship. ZRE recognizes the NIHR Integrated Academic Training programme which supports her Academic Clinical Lectureship post.

**Background**

Osteoporosis causes substantial morbidity globally due to fragility fractures, and consequent associated mortality and healthcare costs (1). Increased fracture risk in both type 1 and type 2 diabetes has been demonstrated across a range of cohorts, despite differences in the underlying pathogenesis (2). In general, patients with type 1 diabetes have greater fracture risk than those with type 2, with some studies suggesting no excess fracture risk in the latter (3-6). However, the role of bone mineral density (BMD) and adiposity (7-9), chronic low-grade inflammation (2,10-13) and microvascular complications (14,15) have not been clearly delineated. Indeed, to our knowledge, no cohort has permitted an integrated investigation across all such questions in a uniformly phenotyped, sufficiently large population.

With over 500,000 participants, UK Biobank offers a unique opportunity to assess the association between diabetes and fractures with robust statistical power, allowing for comprehensive analyses and subgroup assessments (16). In this dataset, diabetes is one of the most prevalent chronic noncommunicable conditions, with around 22,000 cases reported at baseline and a predicted 40,000 incident cases by 2023.

In UK Biobank, we therefore quantified the risk of incident fractures in individuals with type 1 and type 2 diabetes, considering variation by disease duration and diabetic vascular complications (such as retinopathy, neuropathy, peripheral vascular disease), together with independence from estimated bone mineral density by heel ultrasound (eBMD), adiposity and proxies for chronic systemic inflammation and renal function.

**Methods**

*Setting and recruitment*

UK Biobank is a longitudinal population study incorporating over half a million participants recruited during 2006-2010 from across the UK. Individuals aged 40-69 years old were identified through National Health Service (NHS) registers and invited to participate. The baseline assessment, undertaken at regional centres (2006-2010), included detailed review of demographics, lifestyle, medical history, a series of physical measures, and blood sampling. The protocol is publicly available (17). Individuals who were unable to consent or complete baseline assessment due to illness or discomfort were not recruited. Linkage with Hospital Episode Statistics (HES) and death registers enable longitudinal tracking of health outcomes for all participants. This work was undertaken using the UK Biobank resource under approved application 3593.

*Ethics*

This study is covered by the ethical approval for UK Biobank studies from the NHS National Research Ethics Service on 17th June 2011 (Ref 11/NW/0382) and renewed 29th June 2021 (Ref 21/NW/0157).

*Exposure: Diabetes mellitus type 1 or type 2*

The identification of prevalent diabetes cases has been recognised as a challenge in observational studies, as the validity of diabetes self-report varies considerably (18,19). We used the algorithm devised by Eastwood et al. in UK Biobank to classify individuals as either “Diabetes unlikely”, “type 1” or “type 2” (20). This incorporates a combination of self-reported data, nurse interviews and linkage to specific ICD10 codes to assign a status of “probable” or “possible” diabetes. On detailed review of the algorithm, it was judged that the classification of the modest number of individuals with “possible” type 2 diabetes was insufficiently robust to be certain that they did not have type 1 diabetes. We therefore included only cases of “probable” type 2 diabetes in the analysis, together with both “probable” and “possible” cases of type 1 diabetes (where it was judged that both classifications were likely to be robust). We removed from the analysis women with “possible gestational diabetes” due to the short duration and differing pathogenesis of this condition (n=192).

We made the following clinically-informed assumptions: for participants whose age at type 1 diabetes diagnosis was >40 years we assumed that, rather than age of onset, this variable had been input as “years since diagnosis” instead (n=80). Conversely, for participants whose age at type 2 diabetes diagnosis was <10 years we have assumed that number was actually “years since diagnosis” (n=214).

*Microvascular complications of diabetes and comorbidities*

We defined complications of diabetes based on ICD10 codes, from linked HES (and equivalent linkage outside England): G590: Diabetic mononeuropathy; G632: Diabetic polyneuropathy; H280: Diabetic cataract; H360: Diabetic retinopathy; N083: Glomerular disorders in diabetes mellitus. We combined retinopathy and diabetic cataract into eye complications; diabetic polyneuropathy and diabetic mononeuropathy into neuropathy, avoiding double counting if a participant had more than one condition in the same category. Comorbidity count used the conditions listed in the Charlson Comorbidity index (21). In a further analysis we used estimated glomerular filtration rate (eGFR) as a proxy measure of renal function, likely to be altered by renal microvascular disease. We have used the formulae reported in: National Institute of Diabetes and Digestive and Kidney Diseases. Glomerular filtration rate (GFR) estimating equations, outlined below(22).

|  |  |  |
| --- | --- | --- |
| ***Sex*** | ***Serum creatinine, SCr (mg/dL)*** | ***Equation (age in years for ≥ 18)*** |
| *female* | *≤ 0.7* | *GFR = 142 × (SCr/0.7)-0.241 × (0.9938)Age × 1.012* |
| *female* | *> 0.7* | *GFR = 142 × (SCr/0.7)-1.200 × (0.9938)Age × 1.012* |
| *male* | *≤ 0.9* | *GFR = 142 × (SCr/0.9)-0.302 × (0.9938)Age* |
| *male* | *> 0.9* | *GFR = 142 × (SCr/0.9)-1.200 × (0.9938)Age* |

*Outcome: Osteoporotic fracture*

In order to maximise statistical power, we used first incident (after baseline) osteoporotic fracture as the principal outcome, obtained through HES (clinical vertebral, ribs, pelvis, humerus, clavicle, scapula, sternum, hip, other femoral fractures, tibia, fibula, and distal forearm/wrist) (23). ICD9 and ICD10 codes are recorded in the supplementary material (**Supplementary Table 9**). Information on the use of HES data in UK Biobank is given here: <https://biobank.ndph.ox.ac.uk/showcase/refer.cgi?id=138483>.

*Baseline measures*

Heel estimated bone mineral density (eBMD) was derived from quantitative ultrasound (Hologic Sahara, Waltham, MA) at the calcaneus bilaterally in UK Biobank participants, according to a predefined standard operating procedure (24). Quality control checks of the sonometer were undertaken daily using a phantom. QUS parameters have been shown to be independent predictors of fragility fractures and demonstrates moderate associations with BMD measured by dual-energy x-ray absorptiometry (DXA) (25)(26,27). Whole body fat mass was measured by bioimpedance analysis (BIA) (Tanita BC418MA body composition analyser) (28). Standing height was measured using a Seca 202 measuring rod. Body mass index (BMI) was calculated by dividing body weight by the squared height (kg/m2). We considered serum C-Reactive Protein (CRP), as a surrogate for chronic systemic inflammation, and estimated glomerular filtration rate (eGFR) as a marker of renal function. Details of the biochemical methods are available on the UK biobank website (<https://www.ukbiobank.ac.uk/media/oiudpjqa/bcm023_ukb_biomarker_panel_website_v1-0-aug-2015-edit-2018.pdf>). Information on medications was obtained through self-report and nurse interview at baseline.

*Statistical analysis*

Descriptive baseline statistics are presented by diabetic status, using counts and percentages, mean and standard deviations (SD) for normally distributed continuous variables and median with interquartile range (IQR) for other continuous variables.

We investigated the association between diabetes status and heel eBMD, stratified by sex. To delineate the associations between baseline diabetic status and incident osteoporotic fracture, we used Poisson regression models with robust standard errors, since the proportional hazards assumption was not met. Individuals were followed until the first fracture event, death, withdrawal from the database or until 30th September 2021. As well as the unadjusted model, we undertook further models adjusted for the following confounders: sex, age, tobacco use, alcohol use, deprivation index score, level of physical activity, co-morbidities (Model 1), Model 1 + heel eBMD, Model 1 + body fat mass, Model 1 + C-reactive protein, Model 1 + eGFR, Model 1 + heel eBMD + body fat mass + C-reactive protein + eGFR (Model 2). Assumptions notwithstanding, analysis using Cox proportional hazards models gave very similar results, and we therefore undertook Fine and Gray competing risk models to investigate whether mortality modified the effect sizes.

We investigated potential interactions between diabetes status, age, sex, and BMI performing stratified analysis by category of BMI: underweight <18.5 kg/m2; normal weight 18.5-25 kg/m2; overweight 25-30 kg/m2; obese >30kg/m2. We also performed analyses on diabetic complications and tested the associations by different types of complications (eye complications, neuropathy, glomerular disorders) and number of complications on osteoporotic fractures. We analysed the risk of osteoporotic fracture by disease duration (enabling us to compare, for example, those with disease duration of less than a year compared to more than a year, less than two years compared with more than two years, etc.).

Finally, we undertook sensitivity analyses to investigate the effect of our assumptions by 1) omitting those individuals that were reclassified on the basis of disease duration or age of onset, and 2) including those excluded on the basis of classification as “Possible Type 2 Diabetes”.

Statistical analyses were performed using STATA Version 17.0.

**Results**

*Study population*

A total of 498,949 UK Biobank participants were included in these analyses, of whom 1,836 had type 1 diabetes and 20,551 had type 2 diabetes. **Table 1** documents baselinecharacteristics by diabetes status. The mean baseline age was 58 years for those with no diabetes, 55 years with type 1 diabetes and 62 years with type 2 diabetes.

Participants with type 2 diabetes were older, more likely to be male, obese, of South Asian or African Caribbean ethnicity, and with lower levels of college/university education compared with the population without diabetes (**Table 1)**. Comorbidities were more common in individuals with diabetes than those without, and these were more common in those with type 1 diabetes (individuals with 2 or more comorbidities, 26.1% of those with type 2 diabetes, 37.3% of those with type 1 diabetes, 15.1% of those without diabetes). Consistently, the number of diabetic complications was also greater in the type 1 diabetes group (36.8% having two or more diabetic complications, compared with 16% in the type 2 diabetes group). A greater number of deaths during follow-up were observed in participants with diabetes (20% type 1 and 17.9% type 2 diabetes), compared with those without diabetes (6.9%). In participants without diabetes, 5% suffered an incident osteoporotic fracture, compared with 11.9% in individuals with type 1 diabetes and 6.2% in those with type 2 diabetes.

*Associations of type 1 or type 2 diabetes with heel eBMD*

**Table 2** illustrates the relationships between type 1 or type 2 diabetes and heel eBMD. Compared with participants without diabetes, type 1 diabetes was associated with lower heel eBMD whereas type 2 diabetes was associated with higher heel eBMD. These associations were robust to adjustment for fat mass measured by bioimpedance. The magnitude of the associations differed by sex and diabetes type: type 1 diabetes was negatively associated with heel eBMD, more strongly in men than women [after adjustment for fat mass, in men, β -0.03 (95% CI -0.04,-0.02) g/cm2; women β -0.006 (-0.0148, 0.002) g/cm2]. The presence of type 2 diabetes was positively associated with heel eBMD in both women and men, with stronger associations observed in women [(after adjustment for fat mass, in men, β 0.006 (95% CI 0.003, 0.008) g/cm2; in women β 0.015 (0.012, 0.018) g/cm2].

*Diabetes and risk of incident fracture*

**Figure 1 (and Supplementary Table 1)** illustrates that participants with type 1 diabetes (vs those without diabetes) were approximately 3 times more likely than those without diabetes to experience an incident osteoporotic fracture (Model 1; IRR 3.16 (2.56, 3.89), p<0.001). Full adjustment (Model 2) incorporating eBMD, fat mass, CRP and eGFR did not materially alter the observed association (Model 2: IRR 2.93 (2.37, 3.62), p<0.001). Type 2 diabetes was also associated with increased fracture risk albeit with the quantum of effect notably smaller than that with type 1 diabetes. (Model 1: IRR 1.15 (1.04, 1.26), p=0.006). Full adjustment incorporating eBMD, fat mass, CRP, and eGFR again did not materially alter the observed association (Model 2: IRR 1.25 (1.14, 1.38), p<0.001).

In a Fine and Gray competing risk model, adjustment for death hazard did not materially alter the findings but did attenuate the magnitude of the effect of Type 1 diabetes on fracture risk; Type 1 diabetes Model 1: Sub-distribution Hazard Ratio (SHR) 2.46 (2.10, 2.88); Type 2 diabetes Model 1: SHR 1.18 (1.11, 1.27).

There was no evidence of an interaction with either sex or age in the association between incident osteoporotic fracture and diabetes of either type. However, we observed evidence of an interaction between type 2 diabetes (but not type 1 diabetes) and BMI (**Supplementary Table 2**, p interaction = 0.03). Therefore, we performed analysis stratified by BMI (**Figure 2** and **Supplementary Table 3**). In individuals with type 1 diabetes the risk of osteoporotic fracture was raised irrespective of BMI, although there was a trend with increasing risk with increasing BMI category. The association between type 2 diabetes and fractures was however only significant for participants in the overweight or obese categories with similar IRRs of around 1.2. The underweight category is not shown in the figures as the model did not converge due to a very small number of participants in this category.

*Associations between microvascular complications of diabetes and incident fractures*

**Table 3** is restricted to participants with diabetes, and documents that, although any type of microvascular complication was associated with increased risk of fracture, risks were particularly elevated for participants with neuropathy and glomerular disorders which increased risks of fracture by two- or three-fold, irrespective of the type of diabetes. We detected a dose-response effect of number of complications on fracture risk (**Supplementary Table 4**), with risks more than trebling for participants with diabetes (either type 1 or type 2) and at least 2 complications vs those with diabetes and without complications (IRR=3.69; 95%CI 2.78 to 4.91), compared with a doubling for 1 versus no complications (IRR 1.97; 95%CI 1.57, 2.47). The risk of complications was strongly associated with BMI, for example in participants with eye complications, 51% (n=1278) were obese compared to 13% of normal BMI (n=327), and for neuropathies, 57% (n=532) were obese compared to 12% (n=111) of normal BMI (**Supplementary Table 5**).

*Diabetes duration*

**Supplementary Table 6** documents the time specific analyses for relationships between duration of type 2 diabetes and risk of osteoporotic fracture, year on year. The incident rate ratio for fracture became positive at around five years duration, being lower than unity for disease duration less than five years. Thus, the association between diabetes type 2 and osteoporotic fracture was close to unity for disease duration up to 5 years [1.02 (0.89, 1.17)], but with a 28% increase in risk for duration beyond five years [1.28 (1.13, 1.44)].

*Sensitivity analyses*

**Supplementary Table 7** demonstrates our reclassification approach had no material impact on the associations. Since a proportion of the possible type 2 diabetes group will be type I diabetes, the greater magnitude of effect size in the relationship between diabetes and fracture apparent when including these participants is consistent with this assumption (**Supplementary Table 8**).

**Discussion**

In this study using UK Biobank, we demonstrated that both type 1 and type 2 diabetes are associated with increased risk of osteoporotic fractures, with the quantum of effect being greater for type 1 than type 2. There were effects of duration of disease for type 2 and the presence/absence of diabetic microvascular complications for both diabetes types on fracture risk. These associations were not materially modified by consideration of adiposity, heel eBMD, CRP or eGFR. To our knowledge, this is the largest investigation of the associations between diabetes and fracture risk in a single uniformly deeply phenotyped cohort with consistently validated outcome ascertainment.

The increased frequency of osteoporotic fractures in individuals with type 1 and type 2 diabetes compared with those without diabetes is consistent with previous literature (3,4,29), though, converse to our findings, some studies have suggested that type 2 diabetes is not a clinically relevant risk factor for fracture (30). We hypothesise that such null findings reflect shorter duration of disease, particularly given that we observed disease duration-dependent associations between type 2 diabetes and incident fracture risk. Indeed, similarly, in a Canadian study of over 82,000 patients with diabetes (type 1 and type 2 combined), those newly diagnosed had lower fracture risk and those with a longer duration had higher risk for osteoporotic fracture compared with controls without diabetes (31). Our documentation of greater fracture risk with increasing numbers of microvascular complications is also consistent with a dose-response effect in terms of disease severity and duration.

Other studies have also identified opposing associations between type 1 and type 2 diabetes with BMD, with the presence of type 1 diabetes being associated with lower BMD, particularly at the hip (32), and type 2 diabetes being associated with greater BMD (8,33), with BMI as a major determinant of BMD at both the spine and hip (34). The relationships between diabetes, BMI, BMD and fracture risk are complex. In UK Biobank, we found that in patients with type 1 diabetes, fracture risk was elevated regardless of BMI, with a trend towards greater risk in overweight and obese individuals. In those with type 2 diabetes however, we observed no elevation in fracture risk in normal weight individuals but similarly increased risks in overweight and obese individuals. Interestingly, in a nationwide study of patients with diabetes and controls from Scotland, risk of hip fracture was only slightly increased in patients with type 2 diabetes. The risk was dependent on BMI, in that patients with type 2 diabetes and a low BMI had increased risk and those with higher BMI had lower risk (35). In an Italian study (with type 1 and type 2 diabetes combined), consistent with our findings, obese patients with diabetes had higher BMD values than patients with diabetes who were not obese and individuals without diabetes who were obese, but, despite this difference, they still had a greater rate of non-vertebral-non-hip fractures (36). These associations (of increased risks of fracture in diabetes with obesity) were not observed in hip and vertebral fractures, with potential mechanical reasons relating to the types of falls and cushioning effects of fat influencing these trends (37).

The mechanisms linking diabetes and increased fracture risk are believed to be complex and multifactorial. They include increased bone resorption as a consequence of elevated levels of osteoclast stimulation due to the presence of inflammatory cytokines such as interleukin 1 and TNF-alpha (2) . In addition, chronic hyperglycemia leads to the accumulation of advanced-glycation end products (AGEs) which impair osteoblast function. Micro- and macrovascular complications, partly due to greater vascular calcification, impair blood flow to bone tissue, and may compromise bone healing (2). Diabetes also has other sequelae- including renal impairment (which is also partly due to microvascular disease) and consequent renal bone disease. We were able to detect an association between eGFR and incident osteoporotic fractures, and found a small, but significant, effect size indicating a protective effect of better renal function on fracture (IRR=0.99 (95%CI 0.98 to 0.99)) Diabetes-related complications can also affect falls risk (indeed we observed a particular increase in fracture risk associated with peripheral neuropathy in diabetes), as can hypoglycaemic episodes.

These mechanistic considerations are likely to be of relevance to our findings. For example, the greater adiposity associated with type 2 diabetes is likely to be protective for many (but not all) fracture types, via greater BMD, and potentially through biomechanical protection (38). Insulin is anabolic to bone and hyperinsulinaemia in type 2 diabetes may offset bone fragility resulting from hyperglycaemia in early disease, with the negative effect predominating with longer duration (2). Although we did not observe any effect modification by adjustment for CRP, this is only one marker of chronic inflammation(10). Such nuances may further explain some of the heterogeneity between studies noted above.

*Strengths and limitations*

Several limitations should be considered: First, as with many such cohorts, there is evidence of healthy selection bias in UK Biobank compared with the UK population. This may reduce the generalisability of our findings, but notwithstanding, a clinically meaningful distribution of exposures and outcomes was available. Second, it was not possible to undertake meaningful analyses stratified by ethnicity. Third, it is possible that more minor fractures not leading to hospital admission are under-ascertained in the Hospital Episode Statistics data through the use of ICD9 and ICD10 codes; if anything though this would conservatively bias effect estimates. Fourth, whilst we were able to account for a range of confounders, the potential for residual confounding remains, and we cannot infer causality in this setting. Finally, we were not able to use time to event analysis since the proportional hazards assumptions for Cox Regression were not met. However, the findings from Cox regression were similar to those from Poisson regression.

*Clinical implications*

Type 1 diabetes is one of the “secondary osteoporosis” options as an input variable into the current FRAX® calculator, an integral component of over 100 guidelines internationally (39). Although the quantum of the risk relationship with incident osteoporotic fracture is substantially greater for type 1 than type 2 diabetes, our findings confirm those from previous small individual studies and meta-analyses, that type 2 diabetes influences fracture risk independent of clinical risk factors, adiposity and BMD. As such, albeit in a rather complex milieu of influences across body composition, skeletal health and inflammatory processes, our findings clearly support consideration of type 2 diabetes in fracture risk assessment, irrespective of the underlying causal mechanisms. Furthermore, while femoral neck BMD from DXA is the potential input variable for FRAX rather than heel ultrasound eBMD, it is notable that the increased risk of fracture with type 1 diabetes persisted after eBMD adjustment. As a “secondary osteoporosis” risk factor, the effect of type 1 diabetes on fracture risk in FRAX is assumed to be via BMD. Our findings suggest that type 1 diabetes might increase fracture risk beyond what is explained by BMD. Importantly, FRAX2 is under development, and will consider inclusion of type 1 and type 2 diabetes, reflecting BMD dependent and independent effects (40).

*Conclusions*

In conclusion, we have quantified, in the uniquely large and well phenotyped UK Biobank population, the increased fracture risk associated with type 1 or type 2 diabetes. The magnitude of effect appears greater in type 1 than type 2 diabetes, and is at least partly independent of eBMD, adiposity and proxies for renal function and chronic inflammation. Importantly, fracture risk increases with type 2 diabetes disease duration, and is markedly increased with microvascular complications in both diabetes types. Our findings are consistent with the known biology of these conditions, and directly inform approaches to clinical risk assessment, in which skeletal health should form part of overall assessment of all patients with diabetes.

*Acknowledgements*

We are grateful to Eastwood et al for kindly supplying STATA code to enable us to follow their algorithm for diabetes classification (20). For the purpose of Open Access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. This work was undertaken using the UK Biobank resource under approved application 3593. The work was supported by the UK Medical Research Council (MRC) [MC\_PC\_21003; MC\_PC\_21001], National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton, and University Hospital Southampton NHS Foundation Trust, NIHR Oxford Biomedical Research Centre, University of Oxford, Wellcome Trust (209233/Z/17/Z). EMC has been supported by the Wellcome Trust (201268/Z/16/Z), by an NIHR Academic Clinical Lectureship and a grant from the American Society for Bone and Mineral Research. RJM is funded by an NIHR Academic Clinical Lectureship. ZRE recognizes the NIHR Integrated Academic Training programme which supports her Academic Clinical Lectureship post.

*Author contributions*

EMC contributed to the data interpretation and led the manuscript preparation; SD conducted the statistical analyses and contributed to data interpretation and drafting of the manuscript; RJM contributed to data interpretation and drafting of the manuscript; ZR contributed to data interpretation and manuscript revision; CC contributed to data interpretation and review of the manuscript, NCH contributed to study design, study oversight and execution, and preparation of the manuscript and is guarantor.

*Disclosures*

EMC reports lecture fees or travel support from Eli Lilly, Pfizer, Thornton and Ross and UCB, unrelated to this work. RJM has received travel bursaries from Kyowa Kirin unrelated to this work. Amgen, Kyowa Kirin. CC reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Theramex, Shire, Consilient Healthcare, Kyowa Kirin and Internis Pharma, outside the submitted work.

**Data Availability Statement**

All data are available via an access application to UK Biobank. <https://www.ukbiobank.ac.uk/enable-your-research>

**References**

1. Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. NatRevRheumatol. nrrheum.2009.260 pii ;10.1038/nrrheum.2009.260 doi 2010;6(2):99-105.

2. Khosla S, Samakkarnthai P, Monroe DG, Farr JN. Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. Nature reviews Endocrinology. Nov 2021;17(11):685-97. Epub 2021/09/15.

3. Dou J, Wang J, Zhang Q. Differences in the roles of types 1 and 2 diabetes in the susceptibility to the risk of fracture: a systematic review and meta-analysis. Diabetol Metab Syndr. Aug 16 2021;13(1):84. Epub 2021/08/18.

4. Bai J, Gao Q, Wang C, Dai J. Diabetes mellitus and risk of low-energy fracture: a meta-analysis. Aging clinical and experimental research. Nov 2020;32(11):2173-86. Epub 2019/11/27.

5. Davie GS, Pal K, Orton E, Tyrrell EG, Petersen I. Incident Type 2 Diabetes and Risk of Fracture: A Comparative Cohort Analysis Using U.K. Primary Care Records. Diabetes care. Jan 2021;44(1):58-66. Epub 2020/11/06.

6. Ha J, Jeong C, Han KD, Lim Y, Kim MK, Kwon HS, et al. Comparison of fracture risk between type 1 and type 2 diabetes: a comprehensive real-world data. Osteoporos Int. Dec 2021;32(12):2543-53. Epub 2021/08/02.

7. Dufour AB, Kiel DP, Williams SA, Weiss RJ, Samelson EJ. Risk Factors for Incident Fracture in Older Adults With Type 2 Diabetes: The Framingham Heart Study. Diabetes care. Jul 2021;44(7):1547-55. Epub 2021/05/19.

8. Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. European journal of epidemiology. May 2012;27(5):319-32. Epub 2012/03/28.

9. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. The Journal of clinical endocrinology and metabolism. Sep 2006;91(9):3404-10. Epub 2006/06/29.

10. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. Jun 2014;69 Suppl 1:S4-9. Epub 2014/05/17.

11. Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: The potential role of an aged immune system. Ageing research reviews. Jul 2017;36:1-10. Epub 2017/02/23.

12. Jin Y, Sharma A, Carey C, Hopkins D, Wang X, Robertson DG, et al. The expression of inflammatory genes is upregulated in peripheral blood of patients with type 1 diabetes. Diabetes care. Sep 2013;36(9):2794-802. Epub 2013/05/03.

13. Shanbhogue VV, Mitchell DM, Rosen CJ, Bouxsein ML. Type 2 diabetes and the skeleton: new insights into sweet bones. The lancet Diabetes & endocrinology. Feb 2016;4(2):159-73. Epub 2015/09/15.

14. Shanbhogue VV, Hansen S, Frost M, Jørgensen NR, Hermann AP, Henriksen JE, et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. European journal of endocrinology. Feb 2016;174(2):115-24. Epub 2015/11/06.

15. de Waard EAC, de Jong JJA, Koster A, Savelberg H, van Geel TA, Houben A, et al. The association between diabetes status, HbA1c, diabetes duration, microvascular disease, and bone quality of the distal radius and tibia as measured with high-resolution peripheral quantitative computed tomography-The Maastricht Study. Osteoporos Int. Dec 2018;29(12):2725-38. Epub 2018/09/14.

16. Littlejohns TJ, Holliday J, Gibson LM, Garratt S, Oesingmann N, Alfaro-Almagro F, et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nature communications. May 26 2020;11(1):2624. Epub 2020/05/28.

17. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS medicine. Mar 2015;12(3):e1001779. Epub 2015/04/01.

18. Jackson JM, DeFor TA, Crain AL, Kerby TJ, Strayer LS, Lewis CE, et al. Validity of diabetes self-reports in the Women’s Health Initiative. Menopause (New York, NY). 2014;21(8):861-8.

19. Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H. Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. European journal of epidemiology. 2004;19(5):411-6. Epub 2004/07/06.

20. Eastwood SV, Mathur R, Atkinson M, Brophy S, Sudlow C, Flaig R, et al. Algorithms for the Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank. PloS one. 2016;11(9):e0162388.

21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. Epub 1987/01/01.

22. National Institute of Diabetes and Digestive and Kidney diseases eGFR Equations for Adults.

23. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417-27. Epub 2001/07/11.

24. UK BIobank Ultrasound Bone Densitometry. 2011.

25. Moayyeri A, Adams JE, Adler RA, Krieg MA, Hans D, Compston J, et al. Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis. Osteoporos Int. Jan 2012;23(1):143-53. Epub 2011/11/01.

26. Swinton PA, Elliott-Sale KJ, Sale C. Comparative analysis of bone outcomes between quantitative ultrasound and dual-energy x-ray absorptiometry from the UK Biobank cohort. Archives of osteoporosis. 2023/05/30 2023;18(1):77.

27. McCloskey EV, Kanis JA, Odén A, Harvey NC, Bauer D, González-Macias J, et al. Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis. Osteoporos Int. Jul 2015;26(7):1979-87. Epub 2015/02/19.

28. UK BIobank Body composition measurement protocol. 2011.

29. Wang H, Ba Y, Xing Q, Du JL. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ open. Jan 3 2019;9(1):e024067. Epub 2019/01/06.

30. Axelsson KF, Litsne H, Kousoula K, Franzén S, Eliasson B, Lorentzon M. Risk of fracture in adults with type 2 diabetes in Sweden: A national cohort study. PLOS Medicine. 2023;20(1):e1004172.

31. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J. Biphasic fracture risk in diabetes: A population-based study. Bone. 2007/06/01/ 2007;40(6):1595-601.

32. Coll J-C, Garceau É, Leslie WD, Genest M, Michou L, Weisnagel SJ, et al. Prevalence of Vertebral Fractures in Adults With Type 1 Diabetes: DenSiFy Study (Diabetes Spine Fractures). The Journal of Clinical Endocrinology & Metabolism. 2022;107(5):e1860-e70.

33. Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, et al. FRAX underestimates fracture risk in patients with diabetes. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. Feb 2012;27(2):301-8. Epub 2011/11/05.

34. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. Apr 2007;18(4):427-44. Epub 2006/10/28.

35. Hothersall EJ, Livingstone SJ, Looker HC, Ahmed SF, Cleland S, Leese GP, et al. Contemporary Risk of Hip Fracture in Type 1 and Type 2 Diabetes: A National Registry Study From Scotland. Journal of Bone and Mineral Research. 2014;29(5):1054-60.

36. Adami G, Gatti D, Rossini M, Orsolini G, Pollastri F, Bertoldo E, et al. Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. Osteoporos Int. 2020/11/01 2020;31(11):2113-22.

37. Prieto-Alhambra D, Premaor MO, Fina Avilés F, Hermosilla E, Martinez-Laguna D, Carbonell-Abella C, et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. Feb 2012;27(2):294-300. Epub 2011/11/19.

38. Johansson H, Kanis JA, Oden A, McCloskey E, Chapurlat RD, Christiansen C, et al. A meta-analysis of the association of fracture risk and body mass index in women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. Jan 2014;29(1):223-33. Epub 2013/06/19.

39. Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV. A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Archives of osteoporosis. Dec 2016;11(1):25. Epub 2016/07/29.

40. Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest. Oct 24 2023. Epub 2023/10/24.

**Table 1: Characteristics of the sample by diabetes status**

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** | **N (%), median (IQR) or mean (SD)** | | |
|  | No diabetes (n=476562) | Type 1 (n=1836) | Type 2 (n=20551) |
| Sex, male, | 213091 (44.7) | 991 (54.0) | 12985 (63.2) |
| N. years since diagnosis of diabetes | - | 31 (22-39) | 4 (2-8) |
| Age, years | 58 (50-63) | 55 (47-61) | 62 (56-66) |
| Heel eBMD (g/cm2) | 0.54 (0.14) | 0.53 (0.14) | 0.57 (0.16) |
| Fat mass (kg) | 24.5 (9.3) | 24.7 (10.9) | 31.4 (11.8) |
| BMI, kg/m2 | 27.2 (4.6) | 28.2 (5.4) | 31.7 (5.8) |
| Underweight | 2593 (0.6) | 4 (0.2) | 16 (0.1) |
| Normal weight | 159459 (33.7) | 540 (30.1) | 1893 (9.3) |
| Overweight | 203298 (42.9) | 719 (40.0) | 6993 (34.3) |
| Obese | 108389 (22.9) | 533 (29.7) | 11471 (56.3) |
| Ethnicity, |  |  |  |
| European/other | 461879 (97.1) | 1775 (96.7) | 18624 (90.9) |
| South Asian/African Caribbean | 13849 (2.9) | 61 (3.3) | 1870 (9.1) |
| Smoking status |  |  |  |
| Never | 261796 (55.2) | 1009 (55.3) | 9141 (45.0) |
| Previous | 161971 (34.2) | 599 (32.8) | 8991 (44.2) |
| Current | 20116 (10.6) | 217 (11.9) | 2197 (10.8) |
| Alcohol consumption |  |  |  |
| Daily or almost daily | 98051 (20.6) | 342 (18.7) | 2942 (14.4) |
| Three or four times a week | 111493 (23.5) | 333 (18.2) | 3168 (15.5) |
| Once or twice a week | 123359 (26.0) | 438 (23.9) | 4682 (22.9) |
| One to three times a month | 52715 (11.1) | 190 (10.4) | 2519 (12.3) |
| Special occasions only | 53168 (11.2) | 272 (14.9) | 3872 (18.9) |
| Never | 36396 (7.7) | 257 (14.0) | 3271 (16.0) |
| Level of education |  |  |  |
| College/University | 155157 (33.2) | 579 (32.2) | 4617 (23.2) |
| Other prof qualif/HDH/A levels | 154519 (33.1) | 590 (32.8) | 6486 (32.6) |
| GCSE or less | 157522 (33.7) | 632 (35.1) | 8807 (44.2) |
| N. comorbidities |  |  |  |
| 0 | 369280 (77.5) | 796 (43.4) | 12033 (58.6) |
| 1 | 35217 (7.4) | 356 (19.4) | 3150 (15.3) |
| 2+ | 72065 (15.1) | 684 (37.3) | 5368 (26.1) |
| Has diabetic complications | - | 807 (44.0) | 2410 (11.7) |
| Number of complications | - |  |  |
| 1 |  | 510 (63.2) | 2025 (84.0) |
| 2+ |  | 297 (36.8) | 385 (16.0) |
|  |  |  |  |
| C-reactive protein, mg/L | |  |  |  | | --- | --- | --- | | 1.3 (0.7,2.7) | 1.6 (0.8,3.6) | 1.8 (0.9,3.8) | | |  |  |  | | --- | --- | --- | | 1.3 (0.7,2.7) | 1.6 (0.8,3.6) | 1.8 (0.9,3.8) | | |  |  |  | | --- | --- | --- | | 1.3 (0.7,2.7) | 1.6 (0.8,3.6) | 1.8 (0.9,3.8) | |
| Estimated glomerular filtration rate, mL/min/1.73 m² | 94.8 (13.0) | 94.3 (20.1) | 92.6 (15.7) |
|  |  |  |  |
| N. individuals with incident osteoporotic fracture | 23925 (5.0) | 219 (11.9) | 1271 (6.2) |
| Osteoporotic fracture incidence, /1000 person-years | 4.1 (4.0,4.1) | 10.0 (8.8,11.4) | 5.0 (4.8,5.3) |
| N. deaths | 32974 (6.9) | 368 (20.0) | 3675 (17.9) |

**Table 2: association between type 1 and type 2 diabetes versus no diabetes and heel BMD (g/cm2) by sex**

Unadjusted associations, and associations adjusted for fat mass by bioimpedance

β coefficient represents mean difference in heel BMD between each pair of groups.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Women** | | **Men** | |
| **Type 1 diabetes** | N | β (95%CI) g/cm2 | N | β (95%CI) g/cm2 |
| unadjusted | 256170 | -0.005 (-0.013,0.003) | 206245 | -0.028 (-0.038,-0.019) |
| adjusted for fat mass | 252984 | -0.006 (-0.148,0.002) | 202645 | -0.030 (-0.040,-0.021) |
| **Type 2 diabetes** |  |  |  |  |
| unadjusted | 262584 | 0.024 (0.021,0.027) | 217663 | 0.015 (0.012,0.017) |
| adjusted for fat mass | 259287 | 0.015 (0.012,0.018) | 231785 | 0.006 (0.003,0.008) |

**Table 3: Association between microvascular complications of diabetes and incident fracture in comparison to diabetes without complications, stratified by type of diabetes.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Diabetes with any microvascular complication** | | **Diabetes with eye complications** | | **Diabetes with neuropathy** | | **Diabetes with glomerular disorders** | |
|  | n | IRR (95%CI) | n | IRR (95%CI) | n | IRR (95%CI) | n | IRR (95%CI) |
| **Type 1 DM** |  |  |  |  |  |  |  |  |
| Osteoporotic fracture | |  |  |  |  |  |  |  |
| *Unadjusted* | 1836 | 2.28 (1.55,3.33) | 1767 | 2.23 (1.51,3.30) | 1314 | 3.01 (1.91,4.73) | 1836 | 2.28 (1.41,3.67) |
| *Model 1* | 1662 | 1.65 (1.11,2.46) | 1604 | 1.57 (1.05,2.35) | 1188 | 2.28 (1.35,3.85) | 1662 | 2.37 (1.41,3.98) |
| *Model 2* | 1408 | 1.52 (1.00,2.29) | 1363 | 1.41(0.93,2.15) | 1000 | 2.15 (1.25,3.71) | 1408 | 1.86 (0.97,3.59) |
| **Type 2 DM** |  |  |  |  |  |  |  |  |
| Osteoporotic fracture | |  |  |  |  |  |  |  |
| *Unadjusted* | 20551 | 2.28 (1.82,2.87) | 19959 | 1.84 (1.42,2.39) | 18816 | 3.77 (2.65,5.36) | 20551 | 3.53 (2.19,5.68) |
| *Model 1* | 18092 | 2.04 (1.59,2.61) | 17590 | 1.84 (1.38,2.45) | 16604 | 3.15 (2.18,4.55) | 18092 | 2.23 (1.44,3.46) |
| *Model 2* | 15960 | 2.05 (1.59,2.64) | 15522 | 1.76 (1.33,2.32) | 14668 | 3.27 (2.16,4.94) | 15960 | 2.72 (1.68,4.40) |

Diabetic complications: Any of diabetic mononeuropathy, polyneuropathy, cataract, retinopathy, arthropathy, glomerular disorders.

Model 1, covariates: sex, age, tobacco use, alcohol use, deprivation index score, level of physical activity, co-morbidities; model 2 = model 1+ eBMD, fat mass and CRP, and eGFR

**Figure 1: Diabetes and risk of incident osteoporotic fracture**

Model 1, covariates: sex, age, tobacco use, alcohol use, deprivation index score, level of physical activity, co-morbidities; model 2 = model 1+ eBMD, fat mass and CRP, and eGFR

Risk estimates are derived from a Poisson regression model, with robust standard errors

**Figure 2: Type 1 and type 2 diabetes and osteoporotic fracture risk, by BMI category:** normal weight (18.5-25), overweight (25-30), obese (>30kg/m2). Note that Y axis is a logarithmic scale. Model 1, covariates: sex, age, tobacco use, alcohol use, deprivation index score, level of physical activity, co-morbidities